USFDA approves Zydus Lifesciences Tavaborole Topical Solution to treat fungal toenail infections

The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad, India.

Published On 2023-04-12 06:09 GMT   |   Update On 2023-04-12 06:12 GMT
Advertisement

Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Tavaborole Topical Solution, 5% (USRLD: Kerydin Topical Solution).

Tavaborole topical solution is indicated to treat fungal toenail infections. These are the infections that may cause nail discoloration, splitting, or pain.

The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad (India).

Tavaborole Topical Solution, 5% had annual sales of USD 3.1 mn in the United States (IQVIA MAT Feb. 2023). The group now has 361 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

Medical Dialogues team had earlier reported that Zydus Lifesciences Limited had received final approval from the USFDA to manufacture and market Azithromycin Tablets USP, 500 mg (USRLD: Zithromax Tablets). Azithromycin is indicated to treat certain bacterial infections such as bronchitis, pneumonia, sexually transmitted diseases (STD), infections of the ears, lungs, sinuses, skin, throat, and reproductive organs.

Read also: Zydus Lifesciences bags USFDA nod for Azithromycin Tablets to treat certain bacterial infections

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), an Indian Pharmaceutical company is a fully integrated, global healthcare provider. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.

Read also: Zydus Lifesciences bags USFDA approval for Carbidopa and Levodopa Tablets to treat Parkinson's disease symptoms

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News